Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323305890> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4323305890 endingPage "77" @default.
- W4323305890 startingPage "69" @default.
- W4323305890 abstract "Asthma is one of the 4 leading causes of death worldwide. Severe asthma is associated with poor quality of life, decreased life expectancy, and higher health resources consumption such as the use of oral corticosteroids (OCSs). This study aimed to assess the cost-effectiveness of mepolizumab as an add-on compared with the standard care of the Chilean public health system (combined inhaled corticosteroid therapy and a long-acting beta-agonist, short-acting beta-agonist, and OCS).A Markov model was adapted to represent the day-to-day of patients with severe asthma over a lifetime horizon. Deterministic and probabilistic sensitivity analyses were performed to account for the second-order uncertainty of the model. In addition, a risk subgroup analysis was conducted to evaluate the cost-effectiveness of mepolizumab across different risk populations.Mepolizumab produces more benefits than standard of care alone (1 additional quality-adjusted life-year, a decrease of OCS usage, an approximated 11 avoided exacerbations) but it cannot be considered cost-effective in the light of the Chilean threshold (incremental cost-effectiveness ratio: US dollars [USD] 105 967/quality-adjusted life-year vs USD 14 896). Despite this, cost-effectiveness increases in specific subgroups, with an incremental cost-effectiveness ratio of USD 44 819 in patients with eosinophil count ≥ 300 cell/mcL and exacerbation history of at least 4 exacerbations in the past year.Mepolizumab cannot be considered a cost-effective strategy for the Chilean health system. Nevertheless, price discount in specific subgroups improves its cost-effectiveness profile significantly and may offer opportunities for access to specific subgroups." @default.
- W4323305890 created "2023-03-07" @default.
- W4323305890 creator A5019162220 @default.
- W4323305890 creator A5042426811 @default.
- W4323305890 creator A5049448122 @default.
- W4323305890 creator A5057889788 @default.
- W4323305890 creator A5059325998 @default.
- W4323305890 date "2023-05-01" @default.
- W4323305890 modified "2023-10-01" @default.
- W4323305890 title "Cost-Effectiveness of Mepolizumab Add-On in the Treatment of Severe Eosinophilic Asthma in Chile" @default.
- W4323305890 cites W161823661 @default.
- W4323305890 cites W1988758075 @default.
- W4323305890 cites W1996417170 @default.
- W4323305890 cites W2004200914 @default.
- W4323305890 cites W2075699130 @default.
- W4323305890 cites W2084055245 @default.
- W4323305890 cites W2095754126 @default.
- W4323305890 cites W2119771117 @default.
- W4323305890 cites W2135058166 @default.
- W4323305890 cites W2138355864 @default.
- W4323305890 cites W2171124311 @default.
- W4323305890 cites W2317777333 @default.
- W4323305890 cites W2370552689 @default.
- W4323305890 cites W2557643659 @default.
- W4323305890 cites W2604291894 @default.
- W4323305890 cites W2627020416 @default.
- W4323305890 cites W2956280050 @default.
- W4323305890 cites W3092750233 @default.
- W4323305890 cites W3170459552 @default.
- W4323305890 cites W3215994777 @default.
- W4323305890 doi "https://doi.org/10.1016/j.vhri.2022.12.007" @default.
- W4323305890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36889021" @default.
- W4323305890 hasPublicationYear "2023" @default.
- W4323305890 type Work @default.
- W4323305890 citedByCount "0" @default.
- W4323305890 crossrefType "journal-article" @default.
- W4323305890 hasAuthorship W4323305890A5019162220 @default.
- W4323305890 hasAuthorship W4323305890A5042426811 @default.
- W4323305890 hasAuthorship W4323305890A5049448122 @default.
- W4323305890 hasAuthorship W4323305890A5057889788 @default.
- W4323305890 hasAuthorship W4323305890A5059325998 @default.
- W4323305890 hasConcept C112930515 @default.
- W4323305890 hasConcept C126322002 @default.
- W4323305890 hasConcept C159110408 @default.
- W4323305890 hasConcept C187212893 @default.
- W4323305890 hasConcept C2776042228 @default.
- W4323305890 hasConcept C2777037409 @default.
- W4323305890 hasConcept C2777832160 @default.
- W4323305890 hasConcept C2779900020 @default.
- W4323305890 hasConcept C2779951463 @default.
- W4323305890 hasConcept C3019080777 @default.
- W4323305890 hasConcept C515549039 @default.
- W4323305890 hasConcept C64332521 @default.
- W4323305890 hasConcept C71924100 @default.
- W4323305890 hasConceptScore W4323305890C112930515 @default.
- W4323305890 hasConceptScore W4323305890C126322002 @default.
- W4323305890 hasConceptScore W4323305890C159110408 @default.
- W4323305890 hasConceptScore W4323305890C187212893 @default.
- W4323305890 hasConceptScore W4323305890C2776042228 @default.
- W4323305890 hasConceptScore W4323305890C2777037409 @default.
- W4323305890 hasConceptScore W4323305890C2777832160 @default.
- W4323305890 hasConceptScore W4323305890C2779900020 @default.
- W4323305890 hasConceptScore W4323305890C2779951463 @default.
- W4323305890 hasConceptScore W4323305890C3019080777 @default.
- W4323305890 hasConceptScore W4323305890C515549039 @default.
- W4323305890 hasConceptScore W4323305890C64332521 @default.
- W4323305890 hasConceptScore W4323305890C71924100 @default.
- W4323305890 hasFunder F4320307773 @default.
- W4323305890 hasLocation W43233058901 @default.
- W4323305890 hasLocation W43233058902 @default.
- W4323305890 hasOpenAccess W4323305890 @default.
- W4323305890 hasPrimaryLocation W43233058901 @default.
- W4323305890 hasRelatedWork W2005049219 @default.
- W4323305890 hasRelatedWork W2065879558 @default.
- W4323305890 hasRelatedWork W2472742574 @default.
- W4323305890 hasRelatedWork W2557643659 @default.
- W4323305890 hasRelatedWork W2598700445 @default.
- W4323305890 hasRelatedWork W2754292714 @default.
- W4323305890 hasRelatedWork W2920896139 @default.
- W4323305890 hasRelatedWork W3125858761 @default.
- W4323305890 hasRelatedWork W4300981573 @default.
- W4323305890 hasRelatedWork W4323305890 @default.
- W4323305890 hasVolume "35" @default.
- W4323305890 isParatext "false" @default.
- W4323305890 isRetracted "false" @default.
- W4323305890 workType "article" @default.